**HPV Vaccination Dosing**

|  |  |  |
| --- | --- | --- |
| **Age at Initiation** | **Recommended Doses** | **Dosing Schedule** |
| **9 – 14 years** (except immunocompromised persons) | **2** | **0, 6-12 months** (minimum interval between first and second dose is **5 months**)\* |
| **15 – 26 years** (and immunocompromised persons initiating at 9-26 years) | **3** | **0, 1-2, 6 months** (minimum intervals are: **4 weeks** between first and second dose, **12 weeks** between second and third dose, and **5 months** between first and third dose) |
| **27 – 45 years** (based on shared clinical decision-making) | **3** | **0, 1-2, 6 months** (minimum intervals are: **4 weeks** between first and second dose, **12 weeks** between second and third dose, and **5 months** between first and third dose) |
| **Recommended for:** * Females and males age 11 - 12, can start at age 9
* Catch-up vaccination is recommended for both girls and boys through age 26 years who are not adequately vaccinated.
* Shared clinical decision-making is recommended for **some** persons aged 27 – 45 years who are not adequately vaccinated.
* HPV vaccine is not licensed for use in adults >45 years.

References: <https://www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm> / <https://www.cdc.gov/mmwr/volumes/65/wr/mm6549a5.htm>  |
| **Contraindicated:*** Persons with immediate hypersensitivity to yeast
* Pregnancy
 |
| **Ideally, adolescents should complete the series by their 13th birthday.** |
| **HPV Vaccine may be given at the same time as other vaccines.** |

Reference: <https://www.cdc.gov/vaccines/vpd/hpv/hcp/administration.html>

|  |
| --- |
| **HPV Vaccine FAQ** |
| **Q:** If an adolescent, age 9 – 14 years, received two doses of HPV vaccine less than 5 months apart, is the series complete? | **A:** No. The adolescent will require a third dose. The third dose should be given 6 – 12 months after the first dose to complete the series. |
| **Q:** If a person initiates the series before age 26, but does not complete it, can the series be completed after age 26? | **A:** Yes. The series can be completed at age 27 or older.Reference: <https://www.cdc.gov/mmwr/pdf/rr/rr6305.pdf> |
| **Q:** If the HPV vaccination series is interrupted, does it have to be restarted? | **A:** No. Continue the series from where it was interrupted. The number of recommended doses is based on age at administration of the first dose. |
| **Q:** If an adolescent was given the first dose of HPV vaccine before age 15, but it has been over a year since that dose was administered, is the series complete with one additional dose? | **A:** Yes. If the person is not immunocompromised and started the series prior to age 15, they are considered adequately vaccinated with just one additional dose. |
| **Q:** Is a pre-vaccination assessment (PAP test or screening) recommended to determine the appropriateness of HPV vaccination? | **A:** No. If a person has been exposed to a strain of HPV, the vaccine will not be effective against that strain. However, the person can still benefit from protection against other types of HPV if they are already infected with one or more types. |
| **Q:** What are the HPV vaccination recommendations for pregnant women? | **A:** HPV vaccination is not recommended during pregnancy. If a woman becomes pregnant during the series, the remainder of the series should be delayed until she is no longer pregnant. |
| **Q:** Isn’t HPV vaccine recommended to age 45? | **A:** In October 2018, the FDA did approve the expanded use of HPV vaccine to include women and men 27 – 45 years. The current CDC recommendation August 2019 states shared clinical decision-making is recommended for **some** persons aged 27 – 45 years who are not adequately vaccinated. Clinicians can consider discussing HPV vaccination with persons most likely to benefit. Vaccination does not need to be discussed with most adults >26 years. HPV vaccine is not licensed for use in adults >45 years. |

Additional FAQ: <http://www.immunize.org/askexperts/experts_hpv.asp>

Considerations for shared clinical decision-making: <https://www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm>